A large number of varieties have been transferred out of medical insurance. It's really difficult for pharmaceutical companies!

[industry trends of pharmaceutical network] on December 13, Hunan Medical Insurance Bureau and the Department of human resources and Social Security jointly issued the notice on practical implementation Among them, the notice emphasizes that the drugs supplemented by the original province will be digested year by year, the first batch of national key monitoring catalog varieties will be removed preferentially, and the original catalog varieties of the province that have entered the national drug catalog will be classified as the "drugs within the digestion period", and these varieties will also be digested year by year within three years according to the national regulations, and the scope of medical insurance will be cleared Photo source: pharma.com In fact, since July 22, the National Health Insurance Bureau issued the heavyweight document "opinions on establishing the management system of medical insurance treatment list (Draft for comments)", published the details and proportion of medical insurance payment and other relevant policies, and explained the rules of the medical insurance catalog, and clarified the principle of using the national basic drug catalog for each local basic drug system, no longer local After basic drugs are added into the list of basic drugs Recently, many provinces have issued relevant policy notices   For example, on December 12, Anhui Provincial Health Insurance Bureau issued the notice of Anhui Provincial Department of human resources and social security on the implementation of national basic medical insurance, work injury insurance and maternity insurance drug catalogue (2019 version) (hereinafter referred to as the notice), which clearly stated that the first 20 key monitoring drugs published by the National Health Committee would be used in the current medical treatment of the province The varieties in the list of guaranteed drugs and the four varieties that failed in the negotiation of renewal of the contract again in 2017 will be cut out before June 30, 2020, and then the varieties transferred out of the national 2017 version of the medical insurance catalog, the varieties whose approval number has been cancelled by the drug regulatory Department, and the varieties included in the key monitoring by Anhui health and Health Commission will be digested If the above digested varieties are less than 40%, the remaining varieties will be selected to determine the transferred varieties Recently, Tianjin Medical Insurance Bureau also issued the notice of municipal human resources and Social Security Bureau of Tianjin Medical Insurance Bureau on docking the work of national drug catalog in 2019, which excluded 20 kinds of national key monitoring drugs and the varieties transferred out of the catalog in the current round of national medical insurance catalog adjustment from the provincial medical insurance catalog In addition, recently, the 2019 version of medical insurance catalogue 3 of Guangdong Province has been circulated in the industry, or 30 varieties including key monitoring drugs will be removed from the catalogue In fact, according to the past practice, almost all provinces and cities are given the opportunity to supplement each round of national health insurance catalog adjustment However, this round of medical insurance catalog adjustment, since the National Health Insurance Bureau issued the catalog adjustment notice, has already hinted that the local medical insurance supplement will eventually become history Industry insiders predict that in 2020, the key monitoring drugs will face a cliff, and in 2022, the local medical insurance catalogue will become history In fact, since the 2017 version of the national health insurance catalog was published, the industry has generally believed that "the era of high growth expected to enter a catalog has long gone In the context of fee control, it has become the consensus of the industry that "the rest is the king." Due to the unified development of national standards and strict management, local governments are not allowed to make their own catalogues or use flexible methods to supplement the drugs in the catalogues, or to adjust the limited payment scope of drugs in the catalogues, and the local supplement power is basically cancelled, which will have a great impact on only relying on entering the local supplement catalogue to support sales varieties and enterprises All in all, at present, for pharmaceutical enterprises, especially those whose core products are excluded from the national medical insurance catalog or whose provincial supplementary products fail to enter the national catalog, the most urgent task is to stop being complacent In the context of medical insurance cost control, it is advisable to go to a broad market outside the hospital, such as grass-roots units, pharmacies, etc., and there may be more development opportunities.